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Abstract
Objectives. To monitor by power Doppler US (PDUS) the short-term response to anti-TNFa therapy in six
target joints of RA patients; to correlate PDUS findings with clinical assessments and laboratory indices of
disease activity.
Methods. Consecutive RA patients starting anti-TNFa therapy were included and studied at baseline and
3 months later. Clinical (number of tender joints; number of swollen joints; Visual Analogue Scale; DAS28)
and laboratory (ESR and CRP) assessments were performed. All patients were evaluated by PDUS at six
target joints (II MCP, wrist, knee bilaterally). The components of synovitis (synovial hypertrophy, joint
effusion, and power Doppler) were analysed and graded (03 semi-quantitative score). Moreover, by
summing the PDUS findings, three different scores were calculated: a single inflammatory lesion score
(018, for synovial hypertrophy, effusion, power Doppler), a joint score (018; at II MCP, wrist and knee
joints) and a global score (054; sum of all abnormalities).
Results. Sixty-eight RA patients were studied. A significant decrease in the joint score in all articular sites
(MCP, P= 0.003; knee, P= 0.002; wrist, P= 0.0001) as well as in the scores of the single components of
synovitis (P= 0.00010.002) and in the global 6-joint score (P= 0.0001) was found. All clinical and labora-
tory parameters were significantly decreased at follow-up (P= 0.00010.001). A moderate significant posi-
tive correlation was observed between the global PDUS score and DAS28 (r= 0.38; P= 0.001).
Conclusion. PDUS is a sensitive-to-change imaging modality for monitoring the short-term response to
anti-TNFa treatment in RA patients. The assessment of a limited number of joints makes the evaluation
feasible in rheumatology practice as a complementary tool to clinical assessment.
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Rheumatology key messages
. Power Doppler US is a sensitive-to-change imaging modality for monitoring the short-term response to anti-TNFa
treatment in RA patients.
. Use of a feasible sonographic joint count facilitates the application of power Doppler US in daily rheumatology
practice.
Introduction
RA is a chronic inflammatory disease characterized by
symmetrical polyarticular involvement. Synovitis is the
main feature of the inflammatory process [1]. In recent
years, the mechanisms underlying the beginning and the
persistence of the inflammation are becoming clearer, due
to the possibility of observing and understanding the
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cellular subsets and the molecular pattern of cytokines
involved in the process [26]. Among them, TNFa has
been shown to be fundamental in the pathogenesis of
RA, triggering and maintaining the intra-articular inflamma-
tion. It mediates the release of other pro-inflammatory
cytokines (IL1, IL6, IL23), the control of the migration of
leucocytes to sites of inflammation, the upregulation of
the expression of the endothelial adhesion molecules,
the increase in synovial and fibroblastic proliferation, the
progression of the intra-articular damage (cartilage de-
struction and bone resorption), the neovascularization of
the synovial tissue, the activation of the acute-phase re-
sponse, and the production of PGE2, which is responsible
for the possible systemic involvement of the pathology [3,
68]. Consequently, with the major role of TNFa in RA,
anti-TNFa agents represent a revolution in the treatment
of the disease, changing the target of therapy from im-
provement to remission [911]. Therefore, new ways to
define disease activity are required, it being well docu-
mented that lack of symptoms does not necessarily reflect
a lack of joint inflammation; in the case of subclinical syno-
vitis, the possibility of progression of articular damage is
still present [12, 13]. In this scenario, power Doppler US
(PDUS) assumes a relevant role in the evaluation of joint
inflammation. The potential for it to be used in real time, to
estimate both structural damage and inflammatory alter-
ations, along with other advantages such as the absence
of invasiveness and good patient compliance, make PDUS
a very useful technique for monitoring articular disease
activity and the response to anti-TNFa treatment [1416].
Grey scale (GS) US assessment in RA enables visualiza-
tion of joint and peri-articular alterations, such as synovial
hypertrophy, synovial effusion, tenosynovitis, bursitis,
cartilage abnormalities and bone erosions. The PDUS
technique allows the observation of pathological synovial
vascularization that is related to active inflammation
[14, 17]. This finding thus provides the opportunity to dif-
ferentiate between active and inactive synovitis, a differ-
entiation that may influence the therapeutic approach to
achieving remission, if disease is still active, and which
may improve the outcome for the patient [17, 18]. The
intra-articular PDUS signal has a strong correlation with
the radiological progression of the pathology, even in pa-
tients who have reached clinical remission, and it is asso-
ciated with flares [1921]. Therefore, ultrasonographic
assessment in RA can be considered as complementary
to clinical evaluation when seeking to define the most ap-
propriate therapeutic decision for the patient. However,
polyarticular US assessment is time consuming and not
feasible in daily clinical rheumatology practice, and it is
therefore fundamental to identify target joints in RA, for
which assessment could be representative of global dis-
ease activity. The 6-joint score previously demonstrated
validity, sensitivity to change and feasibility for the assess-
ment and monitoring of inflammation in patients with RA
[16]. The objectives of the present study were to use PDUS
to monitor the short-term response to anti-TNFa therapy
in six target joints of RA patients and to correlate PDUS
findings with clinical and laboratory indices of disease
activity.
Patients and methods
A total of 68 consecutive patients, who fulfilled the 2010
RA classification criteria [22] were recruited in the
Rheumatology Unit of the Dipartimento di Medicina
Interna e Specialita` Mediche, Sapienza Universita` di
Roma. All the patients started therapy with an anti-TNFa
agent in association with MTX or other DMARD. Of these,
43 had already been under glucocorticoid treatment for at
least 6 months. Anti-TNFa agents were administered ac-
cording to the Italian Consensus on the use of biologic
drugs for this treatment. The study was conducted in ac-
cordance with the Declaration of Helsinki and was
approved by the local ethics committee (Comitato Etico
Sapienza Universita` di Roma). Informed consent was ob-
tained from all patients enrolled.
Clinical and laboratory evaluation
Clinical evaluation was performed by a single rheumatolo-
gist, blinded to the results of the US assessment that had
been carried out on the same day. Swollen joint count on
28 joints (SJC28), tender joint count on 28 joints (TJC28),
patient visual analogue scale for disease activity (VAS-pa-
tient, 0100 mm), physician visual analogue scale for dis-
ease activity (VAS-physician, 0100 mm) and DAS on 28
joints (DAS28) were registered for each patient on an elec-
tronic database.
Each subject underwent peripheral blood sample col-
lection. ESR (mm/h; normal <20 mm/h; Westergren
method) and CRP (mg/dl; normal range <10 mg/l) were
determined via laboratory tests. Each parameter was
evaluated at baseline and after 3 months.
US evaluation
A single rheumatologist, experienced in musculoskeletal
US, who was blinded to the clinical and laboratory data,
performed the PDUS examination at baseline and at 3
months follow-up. An assessment of six joints (II MCP,
wrist and knee, bilaterally) was performed, with a multi-
planar GS and PD examination, using a MyLab 70 XVision
Gold machine (Esaote, Genova, Italy) with a multifre-
quency linear array transducer (618 MHz; 13 MHz for
the knee, 15 MHz for the wrist and 18 MHz for II MCP).
Settings for PD were: frequency 9.1 MHz, pulse repetition
frequency 750 Hz, PDUS gain 50%, low filters. The US
assessment and scanning technique included evaluation
of the synovial sites in six target joints (wrist—radiocarpal,
midcarpal, ulnocarpal joints; second MCP—dorsal side,
palmar side; knee—suprapatellar recess, lateral parapa-
tellar recess) as previously reported [16]. These joints and
synovial sites were selected according to the previous
study on the 6-joint score by Perricone et al. [16].
According to the OMERACT definitions [23], in each
joint, the presence of synovial effusion (SE) and synovial
hypertrophy (SH) and intra-articular PD signal were
registered as follows: SE as an abnormal hypoechoic or
anechoic intra-articular material that is displaceable and
compressible, but does not exhibit PD signal; SH as an
abnormal hypoechoic intra-articular tissue that is
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non-displaceable and poorly compressible and may ex-
hibit PD signal. The single components of synovitis (SE,
SH, PD) were graded according to a 03 semi-quantitative
score depending on their severity [SE and SH: 0 = absent,
1 = mild, 2 = moderate, 3 = marked; PD signal: 0 = absent
(no synovial flow), 1 = mild (43 PD signals), 2 = moderate
(>3 PD signals in <50% of the synovial area) and
3 = marked (>3 PD signals in >50% of the synovial
area)] [16].
Summing the scores for the elementary lesions in each
joint differently, we calculated: a score for the single
abnormalities in all six joints (the sum of the scores for
each one of the elementary lesions in all six joints: US-
SE score, US-SH score; US-PD score, range 018); a
score for the single joint bilaterally (summing the basic
lesions for each joint; score of the II MCP joint: US-II
MCP, score of the wrist: US-Wrist, score of the knee
US-Knee, range 018); a global score at patient level
(summing all registered alterations at all joint sites,
range 054). An increase in the various scores during
the follow-up was considered to be a worsening of the
pathological process, and a decrease was considered
an improvement.
Statistical analysis
Statistical analysis was performed using SPSS statistical
software, version 13.0 (SPSS, Chicago, IL, USA).
Quantitative variables (DAS-28, US parameters) were
given as the mean (SD) and range. Comparisons between
groups were performed using contingency tables and
Pearson’s test. Comparisons between parametric vari-
ables were performed with the Wilcoxon’s test.
Pearson’s and Spearman’s tests were used to perform
the correlation analysis. Sensitivity to change of the US
variables was tested by comparing the mean change in
US assessment from baseline to 3 months; in addition, we
evaluated the correlation between the changes in US as-
sessment and the variations in DAS-28 from baseline to 3
months (Spearman’s test). Values for P of < 0.05 were
considered statistically significant.
Results
Sixty-eight consecutive patients [11 men and 57 women,
mean age 53 (15.16) years, mean duration of disease
143.6 (41 months)] were included in the study. The main
demographic, clinical and laboratory parameters of the
enrolled population are reported in Table 1.
All the patients started therapy with an anti-TNFa agent
(45 patients: etanercept 50 mg s.c. weekly; 23 patients:
adalimumab 40 mg s.c. every 2 weeks) in association
with MTX or other DMARDs (52 patients; SSZ, HCQ,
LEF, CSA). Forty-three patients started co-treatment
with glucocorticoids. A significant decrease in clinical
and laboratory parameters was registered after 3
months of treatment with respect to baseline (Table 2).
Particularly, DAS28 decreased from a mean value of 5.2 at
basal time, to a mean value of 3.9 at 3 months (P=0.0001);
SJC28 decreased from 7.1 to 3.4 (P= 0,0001); TJC28
decreased from 9.1 to 5.2 at 3 months (P= 0.0001); patient
VAS score was reduced from a mean of 58.2 to a mean of
36.5 (P= 0.0001); physician VAS score had a decrease from
52.3 to 33.8 (P= 0.0009); ESR mean value decreased from
29 to 21.2 mm/h (P=0.001); CRP decreased from 14.9 to
8.7 mg/l (P=0.001).
After 3 months of therapy, a significant reduction in all
three PDUS-analysed scores was registered. Results of
the US assessment are reported in Table 3. Particularly,
in terms of single components of synovitis, the mean
score significantly decreased for SE from 5.2 at baseline
to 3.5 at the 3-month follow-up (P= 0.0001); for SH from
5.3 to 3.2 (P= 0.0001); and for PD from 3 to 1.6 (P= 0.002).
Considering the US joint score, a reduction was regis-
tered at the II MCP (from 2.7 to 1.2; P= 0.003), wrist (from
7 to 4.4; P= 0.0001) and knee (from 4.1 to 2.7; P= 0.0001)
joint levels. Fig. 1 shows the presence of synovitis at the
level of the knee joint at baseline and no evidence of it at
follow-up. At patient level, the global US score decreased
from a basal mean value of 13.9 to a follow-up mean value
of 8.4 (P= 0.0001).
Results emerging from the US evaluation were in sub-
stantial agreement with clinical and serological evaluation.
A significant reduction in DAS28, SJC28, TJC28, patient
VAS for disease activity, and physician VAS for disease
activity was observed after 3 months of treatment. Finally,
a significant correlation between the global PDUS score
TABLE 1 Demographic, clinical and laboratory data of 68
patients at the beginning of therapy with anti-TNFa
Parameter n= 68
Demographic parameters






ESR mean (S.D.), mm/h 29 (21.6)
CRP, mean (S.D.), mg/l 15 (17.3)
Disease activity
VAS physician, mean (S.D.) 52.3 (22.1)
No. of swollen joints, mean (S.D.) 7.1 (6.6)
No. of tender joints, mean (S.D.) 9.1 (7.7)
VAS patient, mean (S.D.) 58.2 (24.9)
DAS28, mean (S.D.) 5.2 (1.3)
Therapy
Corticosteroids, n (%) 43 (63.2)
Anti-TNFa
Etanercept, n (%) 45 (66.2)
Adalimumab, n (%) 23 (33.8)






Anti-TNFa monotherapy, n (%) 7 (10.3)
VAS: visual analogue scale.
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and DAS28 at the 3-month follow-up (R= 0.38, P= 0.0016)
was found.
Discussion
The present US study, conducted in patients affected by
RA and focused on the evaluation of synovial inflamma-
tory alterations (SE, SH and PD signal) in six target joints,
demonstrated a significant decrease in PDUS parameters
considered as indices of the efficacy of anti-TNFa treat-
ment at the 3-month follow-up. Our results demonstrate
that PDUS in six target joints is a useful and feasible tech-
nique for monitoring patients with RA in treatment with
anti-TNFa agents, in relation to its ability to detect synovial
inflammatory abnormalities in real time. The significant
parallel reduction in all clinical and laboratory parameters,
and the correlation between the global PDUS score and
DAS28 at the 3-month follow-up, confirm these aspects.
In the last few decades, the use of musculoskeletal US
as a valid, reliable and sensitive-to-change method for the
evaluation and monitoring of disease activity in RA has
been frequently reported [15, 2428]. Thanks to techno-
logical improvement in US equipment and the use of inter-
nationally approved scanning techniques and definitions
for normal findings and pathology, both GS and PD as-
sessments are widely used in the assessment of inflam-
matory and structural lesions, and in disease follow-up in
relation to early disease. Currently, PDUS represents a
complementary tool for the clinical evaluation of the RA
patient and it plays a role in the determination of joint
inflammatory state and structural damage progression,
in addition to the serological and radiological methods
[17, 18, 2932].
Over the past few decades, a large number of studies
evaluating the efficacy of anti-TNFa treatment and the
sensitivity of musculoskeletal US in monitoring the re-
sponse at joint level have been conducted. Hau et al.
[33] in 2002 published the first US study on the efficacy
of etanercept in five RA patients, evaluating the reduction
of local synovial vascularization at the level of the II MCP
joints. After that, various studies analysed the role of US in
determining the response to anti-TNFa treatment [22, 34,
35] after various intervals of follow-up, highlighting the
correlations between US findings and clinical and labora-
tory parameters.
Even if the sensitivity to change of PDUS is well docu-
mented, a fundamental point has yet to be established:
which and how many joints have to be assessed in the
evaluation of RA patients’ responsiveness? At the
moment, there is a lack of consensus, and in this context,
the present study represents a further application of
Perricone et al.’s work [16], in which we demonstrated
the sensitivity to change and feasibility of US assessment
at the level of six target joints. Because of the typical
polyarticular involvement in RA patients, in clinical
rheumatology practice it is fundamental to obtain a cor-
rect balance between an extended sonographic evalu-
ation (at the level of the involved joints) and a reduced
assessment (at the level of target joints) that proves to
be feasible and easily applied at the bedside. A feasible
TABLE 3 Ultrasonographic data of the 68 patients at the beginning and after 3 months of therapy
Parameter Basal (n= 68) 3 months (n= 68) P-value
US-SE, mean (S.D.) (range 018) 5.2 (3.6) 3.5 (2.4) 0.0001
US-SH, mean (S.D.) (range 018) 5.3 (3.7) 3.2 (2.5) 0.0001
US-PD, mean (S.D.) (range 018) 3 (3.6) 1.6 (1.8) 0.002
US-II MCP mean (S.D.) (range 018) 2.7 (3.9) 1.2 (1.9) 0.003
US-Wrist, mean (S.D.) (range 018) 7.0 (5.0) 4.4 (3.2) 0.0001
US-Knee, mean (S.D.) (range 018) 4.1 (4.3) 2.7 (3.1) 0.002
Global US score, mean (S.D.) (range 054) 13.9 (10.4) 8.4 (6.1) 0.0001
US-SE: ultrasound-synovial effusion; US-SH: ultrasoundsynovial hypertrophy; US-PD: US-power Doppler.






ESR, mean (S.D.), mm/h 29 (21.6) 21.2 (18.6) 0.001
CRP, mean (S.D.), mg/l 14.9 (17.3) 8.7 (10) 0.001
Number of swollen joints, mean (S.D.) 7.1 (6.6) 3.4 (4.8) 0.0001
Number of tender joints, mean (S.D.) 9.1 (7.7) 5.2 (6.5) 0.0001
VAS patient, mean (S.D.) 58.2 (24.9) 36.5 (28.7) 0.0001
VAS physician, mean (S.D.) 52.3 (22.1) 33.8 (23.0) 0.0001
DAS28, mean (S.D.) 5.2 (1.3) 3.9 (1.5) 0.0001
VAS: visual analogue scale.
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US assessment has to be quick to perform and easy to
apply in clinical practice, but it also has to be sensitive to
change. For this purpose, the selection of target joints that
represent the global disease activity is important. The
6-joint assessment has these characteristics, and, in add-
ition, it offers symmetrical evaluation in a disease that has
a typically bilateral involvement. In 2012, we developed a
reduced 6-joint US model after a process of data reduc-
tion on the basis of Naredo et al.’s 2008 work [36]. We first
conducted a 12-joint assessment and, after analysing the
data statistically, significant correlation was found be-
tween the extended evaluation and the 6-joint
assessment.
A number of earlier studies led to the development of
innovative reduced US scores. Particularly, Naredo et al.
[36] in 2008 evaluated the sensitivity to change of a
12-joint assessment (wrist, II MCP, III MCP, knee, ankle
and elbow joints bilaterally) in RA patients under biologic
treatment, obtained by a process of data reduction from
US evaluation of the 44 joints included in the DAS44
index. In 2009, Backhaus et al. [37] proposed a reduced
assessment, the seven US score, evaluating RA synovitis
elementary lesions in the follow-up of anti-TNFa+ MTX
and glucocorticoids therapy. The joints assessed were:
II and III MCP, II and III PIP, II and V MTF, considering
only the clinically dominant side of the body. In 2010,
Hammer et al. [38] proposed an extended assessment
of 78 joints in RA patients in adalimumab therapy; how-
ever, this system proved to be time consuming and not
feasible, although it had a high sensitivity to change.
Hammer et al. in 2011 [39] compared 7- and 12-joint
assessments with 78-joint evaluation in a cohort of 20
patients affected by RA under adalimumab treatment
during a 12-month follow-up period, showing evidence
of a strong correlation between the reduced and the com-
prehensive evaluation, with the advantage of feasibility in
the former. In a systematic review in 2011, Mandl et al.
[40] analysed the literature with respect to the US joint
count and scoring systems for assessment of synovitis
in RA. In order to evaluate the responsiveness and applic-
ability of reduced joint assessment, the data from the 7-
joint score [38] and 12-joint score [36] were taken into
consideration. Based on the data from Naredo’s study,
the 7-joint score was applied and it demonstrated good
responsiveness with the new dataset. Both types of
reduced joint count were sensitive to change and feasible,
although the application of the 7-joint count bilaterally (14
instead of 7 joints) was characterized by a higher sensi-
tivity to change [40]. In 2011, the OMERACT task force
reported data on responsiveness in RA [41]. They intro-
duced the US-GLOSS (US GLObal Synovitis Score), a
combined score (GS + PD) at patient level, assessing 22
paired joints. The US-GLOSS was compared with 7- and
12-joint assessments and all measures were revealed to
have a similar sensitivity to change; from the OMERACT
11 US Workshop, the need emerged for further study of
reduced assessmentsin order to reach consensus on the
number of joints to include [41]. In this context, the
reduced 6-joint count represents a novel joint count that
has increased the possibility of use of PDUS in daily
rheumatology practice assessment of response to treat-
ment. To define the real status of joint inflammation, in
addition to clinical evaluation the importance of including
a US assessment has recently been underlined, particu-
larly PD activity [42, 43]. This aspect may have relevant
consequences for the therapeutic choices required to
achieve real efficacy of treatment [19, 20, 42, 44].
Some limitations in our study should be noted. The use
of a low joint count scoring system during follow-up US
may have underestimated disease activity in patients who
presented a larger number of swollen and tender joints at
baseline; furthermore, subclinical joint involvement could
be missed at the 3-month follow-up, and adjustment of
therapy could be delayed.
In conclusion, the use of reduced assessments, such as
a 6-joint count, in the PDUS evaluation of RA patients is a
useful and feasible method for evaluating the real status of
inflammation and for monitoring the response to treatment
during active disease. In patients in clinical remission, this
count may be useful in analysing the presence of real re-
mission and evaluating the response to treatment. PDUS
in target joints is a feasible method complementary to
FIG. 1 US of the knee joint in a RA patient
Anterior longitudinal scan at the level of the suprapatellar
recess. (A) Synovial hypertrophy and joint effusion are
detected at baseline. (B) No evidence of synovitis is pre-
sent at follow-up.
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clinical assessment for guiding the clinician in the appro-
priate therapeutic decisions.
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